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Recent studies have demonstrated that exosomal microRNAs (miRNAs) are novel 
biomarkers and therapeutic targets for various diseases including vascular disease. 
However, specific exosomal miRNAs expression in stroke patients has not been reported 
yet. Here, we explored whether circulating exosomal miRNAs can serve as potential 
biomarkers for the diagnosis of acute ischemic stroke and discussed the potential for 
clinical application. Blood samples were collected from acute ischemic stroke patients 
within the first 72 h (n = 50). Circulating exosomes were exacted by Exoquick exosome 
isolation kit and characterized by transmission electron microscopy. Western blot was 
performed to assess the expression of exosomal protein makers. Exosomal miRNA-223 
(miR-223) was detected by RT-PCR assay. The relationship between the expression 
levels of miR-223 and National Institutes of Health Stroke Scale (NIHSS) scores, brain 
infarct volume, and neurological outcomes were analyzed. Circulating exosomes were 
isolated and the size of vesicles ranged between 30 and 100 nm. The identification of 
exosomes was further confirmed by the detection of specific exosomal protein markers 
CD9, CD63, and Tsg101. Exosomal miR-223 in acute ischemic stroke patients was 
significantly upregulated compared to control group (p <  0.001). Exosomal miR-223 
level was positively correlated with NIHSS scores (r = 0.31, p = 0.03). Exosomal miR-
223 expression in stroke patients with poor outcomes was higher than those with good 
outcomes (p < 0.05). Increased exosomal miR-223 was associated with acute ischemic 
stroke occurrence, stroke severity, and short-term outcomes. Future studies with large 
sample are needed to assess the clinical application of exosomal miR-223 as a novel 
biomarker for ischemic stroke diagnosis.
Keywords: acute ischemic stroke, biomarker, blood, diagnosis, exosomes, humans, microrna, prognostic
Abbreviations: CE, cardioembolism; DM, diabetes mellitus; LA, large artery atherosclerotic stroke; LACI, lacunar infarct; 
MCAO, middle cerebral artery occlusion; microRNA, miRNA; miR-223, microRNA-223; mRS, modified Rankin Scale; NIHSS, 
National Institutes of Health Stroke Scale; OCSP, Oxfordshire Community Stroke Project; PACI, partial anterior circulation 
infarct; POCI, posterior circulation infarct; ROC, receiver operator characteristic; TACI, total anterior circulation infarct; TEM, 
transmission electron microscopy; TOAST, Trial of Org 10172 in Acute Stroke Treatment.
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inTrODUcTiOn
Stroke is the second leading cause of death in the worldwide, 
bringing heavy burden to the society and families (1). Although 
the morbidity and mortality have been reduced in high-income 
countries due to the public stroke education and the control of 
conventional stroke risk factors, the molecular mechanism of the 
pathogenesis of ischemic stroke still remains unclear.
Generally, the diagnosis of stroke relies on the clinical 
manifestation of the suspected patients and later confirmation 
by Computed Tomography (CT) or MR imaging examination. 
However, it is sometimes difficult for the physicians to make 
objective judgment when the symptom is slight or hard to 
differentiate from other neurological and non-neurological 
diseases. The limitation of brain imaging system in detecting 
small infarcts should also be noticed. Therefore, abundant 
studies on biomarkers have been carried out to provide ideal 
diagnosis for stroke (2–4).
Animal and in vitro experiments demonstrated that microR-
NAs (miRNAs) were involved greatly in stroke pathogenesis by 
regulating oxide stress, inflammation, apoptosis, and endothelial 
function (5–8). Clinical studies also proved that circulating 
miRNAs were potential biomarkers, which could facilitate the 
diagnosis of stroke, the identification of subtype, the evaluation 
of severity, and the prediction of prognosis (9–14).
Exosomes are 30–100  nm vesicles that cells secrete into 
extracellular space when multivesicular bodies fuse with cell 
membrane. Initially, exosomes were regarded as cell garbages to 
remove unwanted proteins. It was not until 2007, when Valadi 
et  al. first identified the existence of RNA and miRNA that 
important role of exosomes was realized—a novel carrier for 
intercellular genetic material exchange and communication (15). 
In recent years, abundant studies provided strong evidence that 
exosomal miRNAs were novel biomarkers and therapy targets 
for various diseases such as tumor, neurodegeneration disease, 
and vascular disease (16–22). However, whether exosomal 
miRNAs can serve as biomarkers for stroke diagnosis remains 
largely unknown.
microRNA-223 (miR-223) was shown to be one of the most 
highly expressed miRNAs in plasma exosomes of healthy human 
and results about its function in ischemia injury are inconsistent 
(23). Here, we designed a retrospective case–control study to 
detect the level of exosomal miR-223 expression in stroke patients 
and non-stroke subjects. We then analyzed the association 
between exosomal miR-223 expression and National Institutes of 
Health Stroke Scale (NIHSS) scores, infarct volume, and modi-
fied Rankin Scale (mRS) in stroke patients. We also discussed the 
potential application of exosomes being novel approach for stroke 
diagnosis and therapy.
MaTerials anD MeThODs
subject and sample collection
Human project was approved by the committee of Institutional 
Review Board (IRB) of Shanghai Jiao Tong University, 
Shanghai, China. Written informed consent was obtained 
from patients according to the Helsinki Declaration, and the 
Helsinki Declaration was followed during the human studies. 
Peripheral blood was collected from stroke patients who were 
recruited consecutively from September 2014 to June 2015 in 
Ruijin Hospital. Control group were enrolled in January 2015 
from subjects who came for medical examination and denied 
previous history of stroke attack. Subjects in each group were 
matched with age and gender. Demography feature, related 
previous history including hypertension, diabetes mellitus 
(DM), hyperlipidemia, cardiopathy, associated laboratory test, 
and imaging information including blood glucose, blood lipid, 
electrocardiogram, cardiac ultrasonography, carotid artery 
ultrasonography, MR imaging, and MR angiography were also 
collected for analysis. The risk factors were defined as the 
following: (1) hypertension: blood pressure ≥140/90  mmHg; 
(2) DM: fasting glucose ≥7.0  mmol/L or 2-h postprandial 
blood glucose ≥11.1 mmol/L; (3) hyperlipidemia: triglycerides 
>1.7 mmol/L or total cholesterol >5.7 mmol/L or low-density 
lipoprotein >4.3 mmol/L. The exclusive criteria included recur-
rent stroke or stroke onset longer than 72  h, renal or liver 
failure, acute infectious disease, tumor, hematologic disease, 
and patients who are unable to cooperate with physical 
examination.
The severity of stroke was evaluated with NIHSS scores. 
The patients were classified into three groups: large artery 
atherosclerotic stroke (LA), cardioembolism (CE), and small 
artery stroke (SA) according to the Trial of Org 10172 in Acute 
Stroke Treatment (TOAST) classification. Patients were also 
classified into the following four groups: total anterior circula-
tion infarct, partial anterior circulation infarct (PACI), posterior 
circulation infarct (POCI), and lacunar infarct (LACI) according 
to Oxfordshire Community Stroke Project (OCSP) definition. 
The infarct volume was calculated by ABC/2 method (A and B 
represent the largest diameter of the infarct and its largest per-
pendicular diameter, while C represents the thickness of the slices 
where the infarct lesion was visible). 3-month mRS was used to 
assess the neurologic outcome of stroke patients.
Blood Preparation and exosomes isolation
Whole blood was drawn into promoting coagulating tubes and 
centrifuged at 1,600 g for 10 min. Serum was aspirated and stored 
at −80°C. ExoQuick exosome precipitation solution (System 
Biosciences, CA, USA) was used to precipitate serum exosomes. 
Briefly, centrifuged the serum sample at 3,000 g for 15 min to 
remove cell debris; Then, added 125  μL ExoQuick exosome 
precipitation solution to 500  μL serum and mixed well; after 
refrigerating at 4°C for 30 min, centrifuged the mixture at 1,500 g 
for 30 min and removed the supernatant; Centrifuged another 
5  min to spin down residual fluid and resuspended exosomes 
pellet by PBS or nuclease-free water. All centrifugations were 
done at 4°C.
exosomes identification
The size and morphology feature of exosomes were examined 
by transmission electron microscopy (TEM) (TEM, Phillip 
CM120, 60 kV). Protein were extracted from exosomes resus-
pension solution with RIPA lysis buffer and separated on 8% 
polyacrylamide gel before transferring to a nitrocellulose filter 
FigUre 1 | (a) The identification of serum exosomes by transmission 
electron microscope. (B) The identification of exosomes specific proteins by 
western blot.
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membrane. The blotting membrane was blocked with skim milk 
and incubated with CD9 antibody (1:1,000 dilution, Abcam, 
Cambridge, UK)/CD63 antibody (1:200 dilution, Santa Cruz 
Biotechnology Inc., Santa Cruz, CA, USA)/TSG101 (1:500 dilu-
tion, Abcam, Cambridge, UK) overnight. After TBST washing, 
secondary HRP-conjugated antibody was added for 1 h (1:5,000 
dilution, HuaAn Biotechnology Inc., Hangzhou, China). 
The proteins were finally detected using chemiluminescence 
(Thermo Scientific, Rockford, IL, USA).
rna extraction and reverse Transcription
Total RNA was isolated from exosomes using miRNeasy Mini Kit 
(Qiagen, Hilden, Germany) mainly according to the manufac-
turer’s instructions. The qiazol volume was 700 µl, and the final 
elute volume was 20  µl. Single-strand cDNA was synthesized 
using universal cDNA synthesis kit (Exiqon, Vedbaek, Denmark) 
following the condition: 42°C for 1 h and then 95°C for 5 min.
real-time Pcr
The expression of miRNA was tested by real-time PCR using 
SYBR Green master mix (Exiqon, Vedbaek, Denmark) on 
an Applied Biosystems 7900 real-time PCR machine (Life 
Technologies). The reaction conditions were as follows: 95°C 
for 10 min followed by 40 cycles of 95°C for 10 s and 60°C for 
1 min. The relative expression of miR-223 was normalized to the 
endogenous control miR-16 expression using the comparative 
cycle threshold (CT) method. When comparing different groups, 
the data were logarithm-transformed.
statistical analysis
Statistics were calculated using SPSS 19 (IBM SPSS Inc., NY, 
USA). The Kolmogorov–Smirnov test was used to determine 
the normality of continuous variables distribution. If normal, 
Student’s t-test was used to compare differences between groups, 
if abnormal, Welch correction was used. Proportions were com-
pared using the chi-square test or Fisher’s test.
To test the feasibility of using miR-223 as a biomarker for stroke, 
we built statistical model by multivariable logistic regression 
analysis. Forward stepwise selection procedures were adopted. 
Results were expressed as adjusted odds ratios (OR) with the 
corresponding 95% confidence intervals (95% CI). Correlations 
were estimated by Pearson correlation test. Differences were 
considered significant at p < 0.05.
resUlTs
The identification of circulating exosomes
Transmission electron microscopy and western blot were used 
for identification of circulating exosomes. On the one hand, the 
yielded vesicles were consistent with exosomes in size and mor-
phology—30–100 nm nano-size and round-shaped (Figure 1A). 
Some researchers showed TEM picture of cup-shaped exosomes 
(24). The shape difference is caused by different methods of pre-
paring sample (25). On the other hand, western blot proved the 
expression of certain exosomal marker proteins, i.e., CD9, CD63, 
and Tsg101 (Figure 1B). CD9 and CD63 are the most commonly 
used marker proteins for exosomes identification. Tsg101 involves 
in transmembrane cargo inclusion and is important for exosomes 
biogenesis (26).
Baseline clinical characteristics
The clinical characteristics of ischemic stroke patients (n = 50) 
and control subjects (n =  33) are shown in Table 1. Mean age 
and the distribution of race/ethnicity were not different between 
two groups (p = 0.67, 1, 1). The number of male in both groups 
was about 1.5 times that of female (p = 0.75). A greater percent-
age of risk factors in stroke patients was found including DM 
36.0% (p < 0.05) and cardiopathy 30.0% (p < 0.05). In our study, 
stroke patients and control group had the similar percentage of 
hypertension (p = 0.98). We considered that this phenomenon 
may be due to the increased awareness of health care in people 
with hypertension. They were more willing to participate in 
our research. The mean NIHSS score of stroke patients was 
relatively low (3.32). According to the TOAST classification, 
50.0% of patients were classified as LA, while cardioembolism 
16.0% and SA 34.0%. A smaller percentage of cardioembolism 
subtype is because that these patients were mostly enrolled to 
the Department of Cardiology in our hospital. According to the 
OCSP classification, 22 stroke patients were classified as PACI, 
while POCI subgroup was 16 cases and LACI subgroup was 11 
cases. Patients with good outcome (mRS ≤ 2) took up 60% and 
those with poor outcome (mRS > 2) accounted for 40%.
exosomal mir-223 expression in acute 
ischemic stroke Patients
In our study, miR-16 was used as internal control. Exosomal miR-
16 level was almost the same between the two groups (Table 2, 
p = 0.828). When compared to control group, the expression of 
TaBle 2 | exosomal mir-16 and mir-223 levels of ischemic stroke 
patients and healthy control.
stroke control p Value
miR-16 CT value (mean ± SD) 21.88 ± 1.18 21.82 ± 1.51 0.828
miR-223 expression (mean ± SD) −0.23 ± 0.30 −0.67 ± 0.28 <0.001
Student’s t-test was used to compare exosomal miR-16/miR-223 levels of stroke 
patients (n = 50) and healthy control (n = 33).
CT, cycle threshold.
TaBle 1 | clinical characteristics of ischemic stroke patients and healthy 
control.
stroke control p-Value
Total (N) 50 33 NA
Race (Asian, %) 100% 100% 1
Ethnicity (Han, %) 100% 100% 1
Age (years, mean ± SD) 64 ± 9.4 63 ± 7.9 0.67
Sex (male/female, N) 32/18 20/13 0.75
Hypertension (N, %) 38 (76.0%) 25 (75.8%) 0.98
Hyperlipidemia (N, %) 29 (58.0%) 14 (42.4%) 0.17
Diabetes mellitus (DM) (N, %) 18 (36.0%) 3 (9.1%) <0.05
Cardiopathy (N, %) 15 (30.0%) 1 (3.0%) <0.05
NIHSS (mean, min, max) 3.32 (0.14) NA NA
TOAST LA 25 (50.0%) NA NA
CE 8 (16.0%) NA NA
SA 17 (34.0%) NA NA
OCSP TACI 1 (2.0%) NA NA
PACI 22 (44.0%) NA NA
Posterior circulation infarct 16 (32.0%) NA NA
LACI 11 (22.0%) NA NA
mRS ≤2 30 (60.0%) NA NA
>2 20 (40.0%) NA NA
The difference of age between stroke (n = 50) and control group (n = 33) were 
compared with Student’s t-test. The proportions of race, sex, hypertension, 
hyperlipidemia, DM, and cardiopathy between two groups were compared with  
chi-square test.
NIHSS, National Institutes of Health Stroke Scale; TOAST, Trial of Org 10172 in Acute 
Stroke Treatment; LA, large artery atherosclerotic stroke; CE, cardioembolism; SA, 
small artery stroke; OCSP, Oxfordshire Community Stroke Project; TACI, total anterior 
circulation infarct; PACI, partial anterior circulation infarct; LACI, lacunar infarct; mRS, 
modified Rankin Scale; NA, not available.
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exosomal miR-223 in the serum of patients with acute ischemic 
stroke were increased greatly (Table 2; Figure 2A, p < 0.001). To 
explore the changing tendency of miR-223 after stroke attack, 
we analyzed circulating exosomal miR-223 levels at 24, 48, and 
72 h. Exosomal miR-223 expression was not significantly differ-
ent between subgroups, although we found it had a tendency to 
increase by time (Figure 2B).
The relationship between exosomal 
mir-223 expression and stroke Onset
To eliminate the unmatched risk factors impact (DM and 
cardiopathy) on exosomal miR-223 expression between two 
groups, we performed a logistic regression analysis. The result 
indicated that circulating exosomal miR-223 expression was a 
possible risk factor of stroke (Table 3, p < 0.001). In addition, 
when the value of exosomal miR-223 increased by 0.1, the 
risk of stroke occurrence increased by about 0.7-fold. The 
receiver operating characteristic curve was drawn to evaluate 
the diagnostic value of exosomal miR-223 (Figure 3). The area 
under the curve was 0.859, when circulating exosomal miR-
223 = −0.50, had the best sensitivity (84.0%) and specificity 
(78.8%) for stroke diagnosis.
The relationship between the expression 
of exosomal mir-223 and characteristics 
of TOasT subtypes, nihss score, infarct 
Volume, and mrs
To explore the relationship between circulating exosomal 
miR-223 and stroke subtypes, we compared exosomal miR-223 
expression in stroke patients with different TOAST subtypes 
(Figure  4A). There was no difference in exosomal miR-223 
level among TOAST subtypes, for example, LA (−0.28 ± 0.27, 
n  =  26), cardioembolism (−0.16  ±  0.19, n  =  7), and SA 
(−0.29 ± 0.31, n = 17, p = 0.53). Patients who were classified 
to cardioembolism seemed to have a higher level of exosomal 
miR-223 but needed further verification with larger sample. To 
examine the association between circulating exosomal miR-223 
and NIHSS score, the Pearson correlation test was performed. 
Positive correlation was found between the exosomal miR-223 
expression and NIHSS score (Figure  4B, r =  0.31, p =  0.03). 
As to the relationship between circulating exosomal miR-223 
and infarct volume, no significant correlation was found in our 
study (Figure 4C, r = 0.20, p = 0.19). To evaluate the relationship 
between circulating exosomal miR-223 and 3-month prognosis, 
we compared the exosomal miR-223 level in stroke patients 
with good outcomes (mRS ≤ 2) and those with poor outcomes 
(mRS > 2). Stroke patients who had poor outcomes were shown 
to have a greater expression of exosomal miR-223 than patients 
who had good outcomes (Figure 4D, −0.1 ± 0.3 vs. −0.3 ± 0.3, 
p = 0.036).
DiscUssiOn
In the present study, we demonstrated that (1) the level of miR-
223 in circulating exosomes was elevated after onset of acute 
ischemic stroke; (2) exosomal miR-223 expression was positively 
correlated to NIHSS score; (3) stroke patients with poor out-
comes inclined to have a greater exosomal miR-223 expression. 
Therefore, increased exosomal miRNA-223 is associated with 
acute ischemic stroke.
Abundant studies have demonstrated the extraordinary 
value of exosomes as strong weapon to diagnose and treat vari-
ous diseases especially cancer (27–30). As to ischemic disease, 
previous studies largely focused on exploring the protection role 
of stem cell-derived exosomes after ischemic injury. Exosomes 
secreted by stem cells like cardiac progenitor cells, mesenchymal 
stem cells, and embryonic stem cells alleviated ischemia–reperfu-
sion injury by delivering functional protein and RNAs (31–34). 
Chopp and colleagues found that systemic administration of 
mesenchymal stem cell-generated exosomes post stroke onset 
improved functional recovery with enhanced neurogenesis and 
angiogenesis (35). This protective role was likely mediated by 
miR-133 enriched exosomes transferring from mesenchymal 
stem cells to neurons and astrocytes (36).
TaBle 3 | exosomal mir-223 expression and the risk of stroke.
Factors adjusted p-value Or 95% ci
miR-223 <0.001 1.70 1.31–2.20
Diabetes mellitus (DM) 0.015 7.84 1.50–40.98
Cardiopathy 0.073 7.72 0.83–72.20
Exosomal miR-223 expression together with conventional stroke risks such as 
hypertension, hyperlipidemia, DM, and cardiopathy were analyzed in a statistical model 
by multivariable logistic regression.
OR, odds ratios; CI, confidence intervals.
FigUre 3 | The receiver operating characteristic curve of serum 
exosomal mir-223 diagnosing ischemic stroke.
FigUre 2 | (a) The expression of miR-223 in serum exosomes of acute ischemic stroke patients was upregulated significantly. The difference of exosomal miR-223 
level between stroke and control group were compared with Student’s t-test. Box plots showed the expression of exosomal miR-223 in patients and control. The 
y-axis indicated miR-223 expression levels by log10 change. ***p < 0.001, stroke patients vs. control. Data are median (25% percentile, 75% percentile), n = 50 in 
stroke group, n = 33 in control group. (B) Serum exosomal miR-223 expression of stroke patients between different onset time. Exosomal miR-223 levels of 
different onset times were compared with one-way ANOVA analysis. Box plots showed the expression of exosomal miR-223 in stroke patients with different onset 
times. The y-axis indicated miR-223 expression levels by log10 change. Data are median (25% percentile, 75% percentile), n = 7 in 24 h subgroup, n = 25 in 48 h 
subgroup, and n = 18 in 72 h subgroup.
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So far there are few clinical studies about exosomes with 
ischemic vascular disease in patients (37, 38). Here, we first 
reported the existence of exosomes in human circulating blood 
with acute ischemic stroke. Exosomal miRNAs, compared to 
total cellular miRNAs or free miRNAs, are considered as more 
sensitive and specific biomarker since exosomes are secreted 
into extracellular space in a selective method (39–42). Chen 
detected the expression of circulating miR-126 and circulating 
exosomal miR-126 in transient middle cerebral artery occlusion 
rats. Exosomal miR-126 decreased significantly 3 h post stroke 
while circulating miR-126 remained unchanged (40). Our study 
further explored the possibility of utilizing exosomal miRNAs as 
novel stroke biomarkers among patients. There was a rise on exo-
somal miR-223 level post stroke, while no alteration in exosomal 
miR-21 and exosomal miR-145 level (unpublished data). miR-21, 
miR-145, and miR-223 are the most well-studied miRNAs that 
are related to hypoxia or ischemia regulation (13, 43–46).
Previous animal experiments revealed miR-223 as a double-
edged sword in functional repair after ischemic injury (47–49). 
One clinical research also showed the same tendency of miR-223 
expression in stroke patients. But the relationship between miR-
223 level and NIHSS score was on the contrary to our study 
(12). The difference might be caused by different sources of 
RNA sample. The mean NIHSS score of stroke patients in our 
study was relatively low, indicating that exosomal miR-223 is 
sensitive for mild stroke. In the prospective population-based 
Bruneck study, reduced miR-223 and other four miRNAs levels 
in plasma antedated the manifestation of DM (50). A recent 
retrospective trail reported that platelet and plasma miR-223 
expression were lower in DM patients with ischemic stroke than 
in DM only patients (51). The study also pointed that platelet 
miR-223 levels were correlated with plasma miR-223 level, but 
not with miR-223 level in leukocytes. In our study, we found 
no difference in serum exosomal miR-223 expression between 
participants with and without DM, or stroke patients with and 
without DM. Whether miR-223 expression was a risk factor for 
stroke in DM patients requires more research. Perhaps different 
sources of miR-223 play different role in stroke pathogenesis. 
miR-223 was reported to be elevated in the serum of patients 
with acute myocardial infarction and angina pectoris (52). But 
there is no hint whether the alteration is sustained in the long 
run. Our stroke patients did not contain patients with acute 
FigUre 4 | correlation analysis between mir-223 and clinical information. (a) Serum exosomal miR-223 expression of stroke patients between different Trial 
of Org 10172 in Acute Stroke Treatment (TOAST) subtypes. Exosomal miR-223 level of different TOAST subtypes were compared with one-way ANOVA analysis. 
The y-axis indicated miR-223 expression levels by log10 change. Box plots showed the expression of exosomal miR-223 in different TOAST subtypes. Data are 
median (25% percentile, 75% percentile), n = 26 in LA, n = 7 in CE, n = 17 in SA. LA, large artery atherosclerotic stroke; CE, cardioembolism; SA, small artery 
stroke. (B) The correlation between exosomal miR-223 level and NIHSS score of stroke patients. The correlations between exosomal miR-223 level and NIHSS 
score was estimated by Pearson’s correlation test (r = 0.31, p = 0.03). The y-axis indicated miR-223 expression levels. NIHSS, National Institutes of Health Stroke 
Scale. (c) The correlation between exosomal miR-223 level and infarct volume. The correlations between exosomal miR-223 level and infarct volume was estimated 
by Pearson correlation test (r = 0.20, p = 0.19). The y-axis indicated miR-223 expression levels. (D) The correlation between exosomal miR-223 level and prognosis 
of stroke patients. The difference of exosomal miR-223 level between good prognosis patients [modified Rankin Scale (mRS) ≤2] and poor prognosis patients 
(mRS > 2) were compared with Student’s t-test. Box plots showed the expression of exosomal miR-223 in patients and control. The y-axis indicated miR-223 
expression levels by log10 change. *p < 0.05, good prognosis patients vs. poor prognosis patients. Data are median (25% percentile, 75% percentile), n = 30 in 
good prognosis group, n = 20 in poor prognosis group.
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coronary syndrome since those patients would likely be sent to 
the Department of Cardiology.
Our study demonstrated that stroke patients with poor 
outcomes turned to have a greater expression of exosomal 
miR-223 (53). Future cohort study can be conducted to tes-
tify the association between higher miR-223 expression and 
lower stroke occurrence. Blocking the secretion and uptake of 
exosomes or regulating exosomal miR-223 expression might 
be necessary to exam the exact role of exosomal miR-223 in 
stroke recovery.
Exosomes, representing a novel approach to carry bioactive 
substances, provides a bright prospect in treating central nervous 
system diseases including stroke (54). On the one hand, these 
nano-sized particles can serve as efficient drug delivering system 
since they can cross blood brain barrier without much degrada-
tion (55). On the other hand, exosomes derived from stem cells 
may minimize adverse effects of administrating cells such as cell 
embolism and excessive cell differentiation (56). Endogenous 
exosomes after hypoxia precondition can also protect the tissue 
from ischemia–reperfusion injury (57). Hence, stem cell-derived 
exosomes or genetically modified exosomes are potential stroke 
treatment.
There are limitations of our study. The sample size was 
relatively small that we failed to further explore the value of 
using exosomal miR-223 to differentiate stroke causes. Future 
study with larger sample is needed. Besides, the blood sample 
was obtained within 72  h after stroke onset. Perhaps, this is 
relatively broad time range to detect the alteration of exosomal 
7Chen et al. Exosomal microRNA-223 for Stroke Diagnosis
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miR-223 level. It is more rational to collect the sample from 
the same patient dynamically at several earlier times such as 
1, 3, 6, 12, 24, and 48  h. The correlation between exosomal 
miR-223 and NIHSS score was relatively weak; thus, it needs 
further investigation.
cOnclUsiOn
This study showed that increased circulating exosomal miR-223 
is associated with acute ischemic stroke occurrence, stroke sever-
ity, and short-term outcome. The clinical value of circulating 
exosomal miR-223 should be further assessed with large sample 
research. Functional studies on the role of exosomal miR-223 and 
its target in ischemic pathogenesis are also essential. We believe 
exosomal miR-223 has potential as a biomarker and a therapeutic 
target for ischemic stroke.
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